Side-by-side · Research reference

ChonlutenvsCJC-1295 (no DAC)

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BPhase 1HUMAN-REVIEWED15/51 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

CJC-1295 (no DAC)

Short-acting GHRH · No DAC variant

100 mcgPer doseTeichman 2006

~30 minHalf-lifeIonescu 2006

Phase 1Evidence levelTeichman 2006 Sigalos 2018

SQ · Pre-sleep · 1–2×/day

01Mechanism of Action

Parameter

Chonluten

CJC-1295 (no DAC)

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

Pituitary GHRH receptorTeichman 2006

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006

Feedback intact?

—

Yes — short pulse preserves somatostatin negative feedbackIonescu 2006

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006

Antibody development

—

Not reported in short-term studies

02Dosage Protocols

Parameter

Chonluten

CJC-1295 (no DAC)

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

1–2× daily (pre-sleep ± morning)

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006 Ionescu 2006

No-DAC variant is less studied directly; PK extrapolated from native GHRH.

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

8–12 weeks on / 4 off (anecdotal)

Clinical validation

None (PubMed indexed)

—

Standard dose

—

100 mcg per injectionTeichman 2006

Often paired with ipamorelin in same syringe.

Lower / starter dose

—

50 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep + fasted preferred

Half-life

—

~30 minIonescu 2006

Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.

04Side Effects & Safety

Parameter

Chonluten

CJC-1295 (no DAC)

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Injection site reaction

—

Erythema, mild pruritus

Flushing / headache

—

Common transient effect

Cortisol elevation

—

Minimal at standard doses

Prolactin elevation

—

Minimal

Glucose intolerance

—

Possible at high cumulative doses

IGF-1 elevation

—

Dose-dependent; monitor with chronic use

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

CJC-1295 (no DAC)

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

CJC-1295 (no DAC)

·Untreated diabetes
·Severe insulin resistance

05Administration Protocol

Parameter

Chonluten

CJC-1295 (no DAC)

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

Subcutaneous, abdomen or thigh. Rotate sites.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

Pre-sleep preferred. Often combined with ipamorelin in the same syringe.

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Chonluten

— no documented stacks

CJC-1295 (no DAC)

+ Ipamorelin

Strong

View Ipamorelin →

CJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.

CJC-1295 (no DAC): 100 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Teichman 2006 Raun 1998